trending Market Intelligence /marketintelligence/en/news-insights/trending/bbhvf7qwkkkkq_sccstqwa2 content esgSubNav
In This List

Atrium to sell biosurgery business to HJ Capital 1 in a strategic shift

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Atrium to sell biosurgery business to HJ Capital 1 in a strategic shift

Atrium Medical Corp., a subsidiary of Getinge AB, will sell its biosurgery business to HJ Capital 1 in a strategic shift to focus on core therapeutic solutions.

Getinge acquired Atrium in 2011 for $680 million, adding the biosurgery arm to its business.

The biosurgery business develops solutions to reinforce soft tissue following injury and surgery. According to Atrium, 2017 the sales of the biosurgery business were about 128 million Swedish kronor.

All assets and liabilities of the biosurgery business will be transferred to HJ Capital 1, excluding surgical mesh product liability claims against Atrium Medical for products sold before the closing of the deal and related insurance claims.

Financial terms of the deal were not disclosed.

HJ Capital 1 operates SeCQure Surgical, which produces medical devices used in general surgical processes.